

**Declaration of Conformity of the Management Board and the Supervisory Board of BioNTech SE
with the German Corporate Governance Code (“Code”) pursuant to Section 161 of the German
Stock Corporation Act (*AktG*).**

The Management Board and Supervisory Board have dealt in detail with the recommendations of the Corporate Governance Code (“Code”) and on 25 February 2026 adopted the following Declaration of Conformity pursuant to Section 161 (1) of the German Stock Corporation Act (*AktG*):

With the exception of the points listed below, BioNTech SE (“Company”) has complied with all recommendations of the Code in the version from 28 April 2022 and will continue to comply with them in the future.

- According to Item B.3 of the Code, the initial appointment of Management Board members shall be for a period of no more than three years. The Company complied with this requirement in the 2025 financial year.
- However, in January 2026, Kylie Jimenez was appointed to the Management Board of BioNTech SE for a term of four years, effective March 1, 2026. Due to the many years of experience and individual qualifications and the creation of the new role of Ms. Jimenez as Chief People Officer, the Company considers an initial appointment of four years to be necessary and appropriate. Furthermore, the Supervisory Board considered the initial appointment for a period of four years to be in the best interest of the Company, as this appointment is in line with the Company’s strategy to become a multi-product oncology company by 2030 and underscores the importance of its global and highly skilled workforce in achieving this objective.
- According to Item C.7 of the Code, it is recommended that more than half of the members of the Supervisory Board be independent of the Company and the Management Board. Accordingly, a Supervisory Board member is independent of the Company and its Management Board if he or she has no personal or business relationship with the Company or its Management Board that could constitute a material and not merely temporary conflict of interest. In assessing independence, the length of service on the Supervisory Board shall be taken into account, among other factors. Despite the fact that two out of six members of the Supervisory Board have been on the Supervisory Board for longer than the twelve years recommended by the Code, all members of the Supervisory Board are considered to be independent. The Supervisory Board considers it advantageous and essential for the Company to maintain the knowledge and experience currently available on the Board. This includes many years of knowledge of the Company and its industry as well as comprehensive professional knowledge in the areas of finance, economics, science and capital markets, which is particularly important in view of the current, steady global growth of, and change in, the Company. Due to the long-standing relationship with the Company and the existing economic independence from the Company, as well as the absence of other concerns that could cause possible conflicts of interest, the length of membership of the two Supervisory Board members Mr. Helmut Jeggle and Mr. Michael Motschmann does not conflict with their respective independence (see Item C.8 of the Code).

Mainz, 25 February 2026

BioNTech SE

Management Board

Prof. Dr. Ugur Sahin
Chief Executive Officer, CEO

Ramon Zapata Gomez
Chief Financial Officer, CFO

Supervisory Board

Helmut Juggle
Chairman of the Supervisory Board